Search for a command to run...
Promoter and Institutional shareholding in Aarey Drugs declined both YoY and QoQ, contrasting with stable sector averages.
Public shareholding has also fallen significantly, indicating a lack of retail confidence in the stock amidst broader sector stability.
Aarey Drugs is underperforming compared to sector trends, especially against the backdrop of the best performer SUDARSHAN, which saw a notable institutional increase.
| Category | Trend | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|
1Promoter9 | 50.04% | 50.04% | 45.27% | 45.27% | 45.43% | 44.8% | 44.8% | 44.8% | |
2Institution2 | 3.92% | 3.83% | 3.4% | 3.4% | 2.67% | 2.34% | 2.34% | 1.73% | |
3Public10 | 4.59% | 4.72% | 7.27% | 7.25% | 4.38% | 5.91% | 8.45% | 5.96% |